These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2672159)

  • 1. [Future perspectives of kidney transplant: towards a specific immunosuppression?].
    Ortiz Arduan A; Gutiérrez JR; Méndez A; Ortiz A
    Rev Clin Esp; 1989 Jun; 185(1):41-3. PubMed ID: 2672159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring immunosuppression following renal transplantation.
    Giorgi JV; Cosimi AB; Colvin RB; Goldstein G; Delmonico FL; Russell PS
    Diagn Immunol; 1983; 1(3):174-8. PubMed ID: 6388969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
    Chatenoud L; Bach JF
    Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A.
    Widmer U; Frei D; Keusch G; Burger HR; Largiader F; Binswanger U
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):90-5. PubMed ID: 3140454
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
    Bonnefoy-Berard N; Revillard JP
    J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting.
    Burke GW; Vercellotti GM; Simmons RL; Howe RB; Canafax DM; Najarian JS
    Transplantation; 1989 Sep; 48(3):403-8. PubMed ID: 2528849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine.
    Thistlethwaite JR; Haag BW; Gaber AO; Stuart JK; Aronson AJ; Mayes JT; Lloyd DM; Stuart FP
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1901-4. PubMed ID: 3103294
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 11. Flow cytometry: its use in pediatric renal transplantation utilizing polyclonal induction.
    Bunchman TE
    Cytometry; 1995 Mar; 22(1):16-21. PubMed ID: 7587728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
    Guttmann RD; Flemming C
    Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
    Friend PJ; Rebello P; Oliveira D; Manna V; Cobbold SP; Hale G; Jamieson NV; Jamieson I; Calne RY; Harris DT
    Transplant Proc; 1995 Feb; 27(1):869-70. PubMed ID: 7879212
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical role of OKT3.
    Norman DJ
    Cardiol Clin; 1990 Feb; 8(1):97-105. PubMed ID: 2407364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-IL-2-receptor monoclonal antibody BT 563 in treatment of acute interstitial renal rejection.
    Carl S; Wiesel M; Daniel V; Staehler G
    Transplant Proc; 1995 Feb; 27(1):854-5. PubMed ID: 7879205
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients.
    Stock PG; Lantz M; Light S; Vincenti F
    Transplant Proc; 1996 Apr; 28(2):915-6. PubMed ID: 8623460
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibodies for the diagnosis and treatment of transplant rejection.
    Russell PS; Colvin RB; Cosimi AB
    Annu Rev Med; 1984; 35():63-81. PubMed ID: 6372674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of renal function using OKT3 in liver transplant patients.
    Millis JM; Baquerizo A; Saleh S; Danovitch GM; Busuttil RW
    Transplant Proc; 1989 Jun; 21(3):3551-2. PubMed ID: 2662524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.